- Home
- MYGN vs KMT Comparison
MYGN vs KMT Comparison
Compare MYGN & KMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- KMT
- Stock Information
- Founded
- MYGN 1991
- KMT 1938
- Country
- MYGN United States
- KMT United States
- Employees
- MYGN N/A
- KMT N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- KMT Industrial Machinery/Components
- Sector
- MYGN Health Care
- KMT Industrials
- Exchange
- MYGN Nasdaq
- KMT Nasdaq
- Market Cap
- MYGN 2.0B
- KMT 1.9B
- IPO Year
- MYGN 1995
- KMT N/A
- Fundamental
- Price
- MYGN $12.39
- KMT $24.28
- Analyst Decision
- MYGN Hold
- KMT Hold
- Analyst Count
- MYGN 12
- KMT 6
- Target Price
- MYGN $23.92
- KMT $27.67
- AVG Volume (30 Days)
- MYGN 1.0M
- KMT 993.2K
- Earning Date
- MYGN 02-25-2025
- KMT 02-05-2025
- Dividend Yield
- MYGN N/A
- KMT 3.30%
- EPS Growth
- MYGN N/A
- KMT N/A
- EPS
- MYGN N/A
- KMT 1.28
- Revenue
- MYGN $823,600,000.00
- KMT $2,036,371,000.00
- Revenue This Year
- MYGN $13.82
- KMT $0.25
- Revenue Next Year
- MYGN $4.59
- KMT $2.49
- P/E Ratio
- MYGN N/A
- KMT $18.94
- Revenue Growth
- MYGN 12.15
- KMT N/A
- 52 Week Low
- MYGN $12.17
- KMT $22.50
- 52 Week High
- MYGN $29.30
- KMT $32.18
- Technical
- Relative Strength Index (RSI)
- MYGN 29.80
- KMT 41.24
- Support Level
- MYGN $12.17
- KMT $23.69
- Resistance Level
- MYGN $15.08
- KMT $24.65
- Average True Range (ATR)
- MYGN 0.79
- KMT 0.58
- MACD
- MYGN -0.01
- KMT 0.14
- Stochastic Oscillator
- MYGN 7.56
- KMT 65.60
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About KMT Kennametal Inc.
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.